al jimi scrap expert LLC

1053 joselson avenue
bayshore, new york 11706

NYS Entity Status
ACTIVE

NYS Filing Date
MARCH 21, 2013

NYS DOS ID#
4377380

County
SUFFOLK

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY

Name History
2013 - AL JIMI SCRAP EXPERT LLC
2013 - AL JIMI SCRAP EXPORT LLC









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • On Cloth Scraps, Syrian Names Are Immortalized in Rust and Blood
    By AVANTIKA CHILKOTI - Wednesday Aug 9, 2017

    Strips of material that a former prisoner smuggled from Syria are now being lent to the United States Holocaust Memorial Museum for an exhibition in Washington.

    Source: NYT > Home Page
  • UN expert: Anti-gay sex laws wane; rights 'crucible' endures
    By JENNIFER PELTZ - Friday Oct 27, 2017

    A U.N. expert says that laws criminalizing consensual gay sex have been scrapped in about 25 countries in the last 20 years.

    Source: Fox News
  • Jimi Hendrix Park Opens at Last, With a Purple Flourish
    By GREGORY SCRUGGS - Sunday Jun 18, 2017

    The green space in Seattle has been caught up in a decade of delays and financial woes. Its ribbon-cutting came on the 50th anniversary of Monterey Pop.

    Source: NYT > Home Page
  • Women of Sex Tech, Unite
    By ANNA NORTH - Friday Aug 18, 2017

    New York is becoming a cultural center for young women trying to disrupt the male-dominated industries of design engineering and sex toys.

    Source: NYT > Home Page
  • The Top 10 Moments of New York Fashion Week
    By THE NEW YORK TIMES - Friday Sep 15, 2017

    Highlights from the shows, including a celebrity-packed front row at Calvin Klein and a trek to Bedford Hills, N.Y., to see Ralph Lauren’s vintage cars.

    Source: NYT > Home Page
  • Acorda Scraps One Parkinson’s Drug, Puts Its Cash Behind Another
    By Frank Vinluan - Monday Nov 20, 2017

    Acorda Therapeutics said Monday that it will stop work on an experimental treatment for Parkinson’s disease, spelling the end for a drug the Ardsley, NY, company added to its pipeline last year in a $363 million deal. The announcement follows the recent emergence of safety problems for the Acorda (NASDAQ: ACOR) drug, tozadenant. Acorda said […]

    Source: Xconomy New York